방사성 의약품/핵의학 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Radiopharmaceutical/Nuclear Medicine Market size is expected to reach USD 39.51 Billion in 2034 from USD 21.78 Billion (2025) growing at a CAGR of 6.84% during 2026-2034.

The Global Radiopharmaceutical/Nuclear Medicine Market has grown steadily with increasing utilization of nuclear imaging techniques for disease diagnosis and treatment. Radiopharmaceuticals are widely used in oncology, cardiology, and neurology for precise imaging and targeted therapy. Rising prevalence of cancer and cardiovascular diseases has accelerated demand for advanced diagnostic tools. Improvements in imaging technologies such as PET and SPECT have enhanced accuracy and early detection capabilities.

Key drivers include growing investments in healthcare infrastructure and expanding adoption of personalized medicine approaches. Technological innovations in radioisotope production and targeted radiotherapy have broadened therapeutic applications. Aging populations in developed regions contribute significantly to demand, as older individuals are more prone to chronic diseases. Regulatory approvals for novel radiopharmaceutical agents further stimulate market expansion, encouraging pharmaceutical companies to invest in research and development initiatives.

Future prospects are promising with the development of theranostic approaches that combine diagnosis and therapy. Expansion of cyclotron facilities and improved distribution networks will enhance accessibility in emerging markets. Collaborations between research institutions and healthcare providers are expected to accelerate innovation. As precision oncology advances, radiopharmaceuticals will likely become integral to targeted treatment strategies, driving sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Diagnostic
• Therapeutic

By Source

• Nuclear Reactors
• Cyclotrons

By End User

• Hospitals
• Diagnostic Centers
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Others

COMPANIES PROFILED

• Novartis AG, Siemens Healthineers AG, Bayer AG, GE HealthCare, Lantheus, Curium, Jubilant Radiopharma, Eckert Ziegler, Cardinal Health, Telix Pharmaceuticals Limited, Bracco, Lilly, AstraZeneca

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Diagnostic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Nuclear Reactors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cyclotrons Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Source
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Source
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Source
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Source
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Source
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Siemens Healthineers AG
  • 9.2.3 Bayer AG
  • 9.2.4 GE HealthCare
  • 9.2.5 Lantheus
  • 9.2.6 Curium
  • 9.2.7 Jubilant Radiopharma
  • 9.2.8 Eckert & Ziegler
  • 9.2.9 Cardinal Health
  • 9.2.10 Telix Pharmaceuticals Limited
  • 9.2.11 Bracco
  • 9.2.12 Lilly
  • 9.2.13 AstraZeneca